Evidence map›Paper›PMID 25064228›Full record

ArticlePediatric surgery international2014

Histological features of primary tumors after induction or high-dose chemotherapy in high-risk neuroblastoma.

Tomoro Hishiki, Hiroshi Horie, Yasuyuki Higashimoto, Katsumi Yotsumoto, Shugo Komatsu, Yuri Okimoto, Harumi Kakuda, Yuichi Taneyama, Takeshi Saito, Keita Terui and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Pediatric surgery international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Clinical impact of primary tumourInternational journal of clinical oncology · 2022
    Article
  5. Comparison Between Diffusion-Weighted MRI andJournal of magnetic resonance imaging : JMRI · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 2 countries.

Tomoro HishikiDepartment of Pediatric Surgery, Chiba Children's Hospital, 579-1 Heta-cho, Midori-ku, Chiba, 266-0007, Japan, hishiki-tmr@umin.ac.jp.
Hiroshi Horie
Yasuyuki Higashimoto
Katsumi Yotsumoto
Shugo Komatsu
Yuri Okimoto
Harumi Kakuda
Yuichi Taneyama
Takeshi Saito
Keita Terui
Tetsuya Mitsunaga
Mitsuyuki Nakata
Hidemasa Ochiai
Moeko Hino
Kumiko Ando
Hideo Yoshida
Jun Iwai
Chiba University · JPBoston Children's Hospital · USChiba Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIn the recent years in Japan, an increasing number of patients with neuroblastoma (NB) are being treated by the "delayed local treatment (DL)" policy, undergoing surgery after the completion of high-dose chemotherapy with hematopoietic stem cell rescue (HDC). We reviewed the histopathological findings of second-look operations, including those of patients treated with DL. PATIENTS: From 1998 to 2013, 26 patients with high-risk NB underwent radical operation following chemotherapy. Surgery was performed after induction chemotherapy in 17 cases (standard; STD), whereas 9 cases completed induction chemotherapy and HDC before undergoing tumor resection (DL). The amount of necrosis and the degree of differentiation within the post-treatment tumor were assessed.

resultsEighty-eight percent of the tumors showed necrosis in more than 1/3 of the specimen. Two DL cases showed complete disappearance of viable tumor cells. Amount of necrosis did not affect the prognosis of the patient. Tumors with immature, poorly differentiated phenotypes showed an extremely aggressive thereafter. Though not statistically proven, (123)I-MIBG (metaiodobenzylguanidine) uptake may be correlated with the amount of viable cells remaining within the tumor, but not with the degree of differentiation.

conclusionsOur results support the previous reports advocating that tumors that sustain unfavorable histology after chemotherapy behave aggressively thereafter.

Indexed as

3-IodobenzylguanidineAntineoplastic Combined Chemotherapy ProtocolsChildChild, PreschoolFemaleFollow-Up StudiesHumansInduction ChemotherapyInfantJapanMaleNeuroblastomaRadionuclide ImagingRadiopharmaceuticalsRetrospective StudiesSecond-Look Surgery3-IodobenzylguanidineRadiopharmaceuticals

Identifiers

PMID25064228
OpenAlexW1968975254

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.